Innate Pharma Asset Resilience Ratio
Innate Pharma asset resilience ratio. Innate Pharma (IPHA) has an Asset Resilience Ratio of 9.91% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See Innate Pharma defensive liquidity buffer to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Innate Pharma (2005–2025)
Asset resilience ratio of Innate Pharma from 2005 to 2025. This chart shows how Innate Pharma's Asset Resilience Ratio has changed over time. Read IPHA liabilities breakdown for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Innate Pharma's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see Innate Pharma (IPHA) total assets.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $6.22 Million | 9.91% |
| Total Liquid Assets | $6.22 Million | 9.91% |
Asset Resilience Insights
- Limited Liquidity: Innate Pharma maintains only 9.91% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Innate Pharma Industry Peers by Asset Resilience Ratio
Compare Innate Pharma's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Hyloris Developmentsen Sa
BR:HYL |
Biotechnology | 1.36% |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 0.00% |
|
Oruka Therapeutics, Inc.
NASDAQ:ORKA |
Biotechnology | 53.11% |
|
Gempharmatech Co. Ltd. A
SHG:688046 |
Biotechnology | 23.95% |
|
Vor Biopharma Inc
NASDAQ:VOR |
Biotechnology | 74.48% |
|
Inventiva S.A
PA:IVA |
Biotechnology | 52.73% |
|
Sunmax Biotechnology Co Ltd
TWO:4728 |
Biotechnology | 10.53% |
|
Guangdong VTR Bio-Tech Co Ltd
SHE:300381 |
Biotechnology | 4.98% |
Innate Pharma Asset Resilience Ratio by Year (2005–2025)
Innate Pharma asset resilience ratio by year from 2005 to 2025. The table below shows the annual Asset Resilience Ratio data for Innate Pharma.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 9.91% | $6.22 Million | $62.69 Million | -3.03pp |
| 2024-12-31 | 12.94% | $14.37 Million | $111.06 Million | +0.47pp |
| 2023-12-31 | 12.47% | $21.85 Million | $175.19 Million | +4.17pp |
| 2022-12-31 | 8.30% | $17.26 Million | $207.86 Million | +2.29pp |
| 2021-12-31 | 6.01% | $16.08 Million | $267.50 Million | +1.18pp |
| 2020-12-31 | 4.83% | $14.85 Million | $307.42 Million | +0.85pp |
| 2019-12-31 | 3.98% | $15.98 Million | $401.36 Million | +0.61pp |
| 2018-12-31 | 3.37% | $15.22 Million | $451.22 Million | -3.19pp |
| 2017-12-31 | 6.57% | $16.74 Million | $255.02 Million | -1.17pp |
| 2016-12-31 | 7.74% | $21.78 Million | $281.58 Million | -19.41pp |
| 2015-12-31 | 27.14% | $83.04 Million | $305.96 Million | +21.68pp |
| 2014-12-31 | 5.46% | $4.95 Million | $90.69 Million | +0.11pp |
| 2013-12-31 | 5.35% | $2.99 Million | $55.88 Million | +1.14pp |
| 2012-12-31 | 4.21% | $2.03 Million | $48.30 Million | -1.55pp |
| 2010-12-31 | 5.76% | $2.76 Million | $48.01 Million | +1.48pp |
| 2009-12-31 | 4.28% | $2.75 Million | $64.22 Million | -33.43pp |
| 2008-12-31 | 37.70% | $22.95 Million | $60.86 Million | -38.78pp |
| 2007-12-31 | 76.48% | $48.30 Million | $63.15 Million | -1.01pp |
| 2006-12-31 | 77.49% | $53.66 Million | $69.25 Million | +13.87pp |
| 2005-12-31 | 63.62% | $15.76 Million | $24.77 Million | -- |
About Innate Pharma
Innate Pharma S.A. operates as a biotechnology company that develops immunotherapies for cancer patients in France and internationally. The company's products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma; IPH4502, a novel and differentiated topoisomerase I inhibitor ADC conjugated t… Read more